CB-183,315 + Placebo + Vancomycin
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Clostridium Difficile Infection
Conditions
Clostridium Difficile Infection, Diarrhea
Trial Timeline
Apr 1, 2010 → May 13, 2011
NCT ID
NCT01085591About CB-183,315 + Placebo + Vancomycin
CB-183,315 + Placebo + Vancomycin is a phase 2 stage product being developed by Merck for Clostridium Difficile Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT01085591. Target conditions include Clostridium Difficile Infection, Diarrhea.
What happened to similar drugs?
7 of 20 similar drugs in Clostridium Difficile Infection were approved
Approved (7) Terminated (3) Active (13)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01085591 | Phase 2 | Completed |
Competing Products
20 competing products in Clostridium Difficile Infection